CoChat

LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

Open access

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Fibroblast growth factor 21 (FGF21) is a novel metabolic regulator that represents a promising target for the treatment of several metabolic diseases. Administration of recombinant wild type FGF21 to diabetic animals leads to a dramatic improvement in glycaemia and ameliorates other systemic measures of metabolic health. Here we report the pharmacologic outcomes observed in non-human primates upon administration of a recently described FGF21 analogue, LY2405319 (LY). Diabetic rhesus monkeys were treated subcutaneously with LY once daily for a period of seven weeks. The doses of LY used were 3, 9 and 50 mg/kg each delivered in an escalating fashion with washout measurements taken at 2, 4, 6 and 8 weeks following the final LY dose. LY therapy led to a dramatic and rapid lowering of several important metabolic parameters including glucose, body weight, insulin, cholesterol and triglyceride levels at all doses tested. In addition, we observed favorable changes in circulating profiles of adipokines, with increased adiponectin and reduced leptin indicative of direct FGF21 action on adipose tissue. Importantly, and for the first time we show that FGF21 based therapy has metabolic efficacy in an animal with late stage diabetes. While the glycemic efficacy of LY in this animal was partially attenuated its lipid lowering effect was fully preserved suggesting that FGF21 may be a viable treatment option even in patients with advanced disease progression. These findings support continued exploration of the FGF21 pathway for the treatment of metabolic disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0065763

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Effects of administration of a dose escalation of LY2405319 on body mass (A) and food intake (B). Differences considered significant (p<0.05) are denoted by *.
Figure 1 Effects of administration of a dose escalation of LY2405319 on body mass (A) and food intake (B). Differences considered significant (p<0.05) are denoted by *.CC BY · PubMed Central
Figure 2 Weekly measurements of circulating glucose (A), triglycerides (B), total cholesterol (C), VLDL cholesterol (D), LDL cholesterol (E) and HDL cholesterol (F) throughout the duration of the study. Differences considered significant (p<0.05) are denoted by *.
Figure 2 Weekly measurements of circulating glucose (A), triglycerides (B), total cholesterol (C), VLDL cholesterol (D), LDL cholesterol (E) and HDL cholesterol (F) throughout the duration of the study. Differences considered significant (p<0.05) are denoted by *.CC BY · PubMed Central
Figure 3 Prominent hormones such as insulin (A), leptin (B) and adiponectin (C) were found to be regulated by LY2405319. Differences considered significant (p<0.05) are denoted by *.
Figure 3 Prominent hormones such as insulin (A), leptin (B) and adiponectin (C) were found to be regulated by LY2405319. Differences considered significant (p<0.05) are denoted by *.CC BY · PubMed Central
Figure 4 Data from J-15 are presented as a separate figure given more advanced disease state of this animal at study onset. As with the other animals we describe glucose (A) and insulin (B) in addition to body weight change (C), food intake (D) along with circulating levels of triglycerides (E), total cholesterol (F), VLDL cholesterol (G), LDL cholesterol (H) and HDL cholesterol (I). Furthermore, adiponectin (J) and leptin (K) were also determined. Differences considered significant (p<0.05) are denoted by *.
Figure 4 Data from J-15 are presented as a separate figure given more advanced disease state of this animal at study onset. As with the other animals we describe glucose (A) and insulin (B) in addition to body weight change (C), food intake (D) along with circulating levels of triglycerides (E), total cholesterol (F), VLDL cholesterol (G), LDL cholesterol (H) and HDL cholesterol (I). Furthermore, adiponectin (J) and leptin (K) were also determined. Differences considered significant (p<0.05) are denoted by *.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 169

Metadata

Authors
Adams, A. C., Halstead, C. A., Hansen, B. C., Irizarry, A. R., Martin, J. A., Myers, S. R., Reynolds, V. L., Smith, H. W., Wroblewski, V. J., & Kharitonenkov, A.
Affiliations
  • Eli Lilly (United States) (US)
  • University of South Florida (US)
Corresponding author
Kharitonenkov, Alexei
Venue
PLoS ONE
Published
2013-06-18
Volume
8
Issue
6
Pages
e65763
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1972717747
Cited by
169
References
24
Citations by year
2026: 2 · 2025: 12 · 2024: 19 · 2023: 11 · 2022: 14 · 2021: 16 · 2020: 8 · 2019: 12 · 2018: 10 · 2017: 17 · 2016: 12 · 2015: 22 · 2014: 11 · 2013: 3
FWCI
7.17
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Eli Lilly and Company
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
FGF21 analogues, FGF21, type 2 diabetes, rhesus monkeys, glycemic control, lipid lowering, adiponectin, leptin, adipose tissue, insulin
MeSH terms
Animals, Blood Glucose, Energy Intake, Diabetes Mellitus, Experimental, Dose-Response Relationship, Drug, Fibroblast Growth Factors, Insulin, Macaca mulatta, Weight Loss, Disease Progression, Adipokines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys. https://app.cochat.ai/papers/10.1371/journal.pone.0065763
The paper
Adams, A. C., Halstead, C. A., Hansen, B. C., Irizarry, A. R., Martin, J. A., Myers, S. R., Reynolds, V. L., Smith, H. W., Wroblewski, V. J., & Kharitonenkov, A. (2013). LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys. PLoS ONE. https://doi.org/10.1371/journal.pone.0065763

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.